Skip to main content
SpringerLink
Log in

ICER announcements: May 2018

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Comparative Effectiveness Public Advisory Council

  2. $100 000−$150 000 per QALY gained

References

  1. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Releases Draft Evidence Report on Elagolix for Endometriosis. Internet Document : 4 May 2018. Available from: URL: https://icer-review.org/announcements/endometriosis-draft-report/.

  2. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Finds that at Current Prices CFTR Modulators for Cystic Fibrosis Improve Patient Outcomes at Costs that Far Exceed Standard Cost-effectiveness Levels. Internet Document : 3 May 2018. Available from: URL: https://icer-review.org/announcements/cf-evidence-report/.

  3. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Posts Draft Scoping Document on Biologic Treatments for Asthma. Internet Document : 15 May 2018. Available from: URL: https://icer-review.org/announcements/asthma-scoping-doc-2018/.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER announcements: May 2018. PharmacoEcon Outcomes News 803, 1 (2018). https://doi.org/10.1007/s40274-018-4928-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4928-9

Search

Navigation